Demographic and clinical characteristics of patients with ITP
| Experiment/category of ITP samples based on disease progression . | No. of samples . | Sample ID . | Sex . | Age, y . | Platelet count at time of blood draw, × 109/L . | Time from diagnosis . | Recent treatments (within 1 mo of sample collection) . | Additional information . |
|---|---|---|---|---|---|---|---|---|
| Microarray and/or real-time PCR | ||||||||
| Self-limited acute ITP (blood was collected within 6 mo of diagnosis when the patients had active disease; patients resolved within 6 mo) | 8 | 1* | M | 4 | 2 | 1 d | IVIG | — |
| 2* | M | 4 | 98 | 3 d | IVIG | — | ||
| 3* | F | 14 | 39 | 1 wk | — | — | ||
| 4* | M | 5 | 44 | 1 mo | — | — | ||
| 5* | M | 1 | 35 | 1 mo | — | — | ||
| 6* | M | 13 | 51 | 1 wk | — | — | ||
| 7* | M | 5 | 126 | 2 mo | — | — | ||
| 8* | M | 3 | 146 | 1 wk | — | — | ||
| Progression to chronic ITP (blood was collected within 6 mo of diagnosis, and the patient did not resolve by 6 mo) | 7 | 9* | M | 1 | 24 | 2 wk | IVIG | — |
| 10* | F | 1 | 6 | 2 mo | Steroids | — | ||
| 11* | M | 1 | 39 | 2 mo | — | — | ||
| 12* | F | 9 | 3 | 4 mo | — | — | ||
| 13 | M | 1 | 30 | 5 mo | — | — | ||
| 14 | F | 18 | 49 | 5 mo | — | — | ||
| 15 | F | 6 | 1 | 1 mo | — | — | ||
| Resolved acute ITP (blood was collected after the patient resolved from self-limited acute ITP) | 6 | 16 | M | 4 | 325 | 3 mo | — | — |
| 17 | M | 5 | 249 | 6 mo | — | — | ||
| 18 | M | 1 | 342 | 8 mo | — | — | ||
| 19 | M | 1 | 216 | 3 wk | IVIG | — | ||
| 20 | M | 4 | 276 | 7 mo | — | — | ||
| 21 | M | 4 | 270 | 1 mo | — | — | ||
| Chronic ITP (blood was collected after 6 mo of diagnosis when the patient had active disease) | 15 | 22* | F | 7 | 8 | 2 y | — | Resistant to multiple treatments |
| 23* | F | 13 | 137 | 7 y | — | |||
| 24* | F | 18 | 3 | 6 y | Imuran | Resistant to multiple treatments; splenectomized | ||
| 25* | F | 8 | 111 | 1 y | — | |||
| 26* | M | 5 | 19 | 8 mo | Steroids | — | ||
| 27* | F | 9 | 80 | 3 y | — | — | ||
| 28* | M | 12 | 21 | 1 y | — | — | ||
| 29* | M | 13 | 80 | 3 y | — | — | ||
| 30* | M | 10 | 18 | 7 y | Imuran | Resistant to multiple treatments; splenectomized | ||
| 31* | M | 5 | 53 | 1 y | Bactrim for impetigo | |||
| 32* | M | 14 | 61 | 11 y | — | Resistant to multiple treatments | ||
| 33* | F | 5 | 85 | 3 y | — | — | ||
| 34* | M | 18 | 18 | 9 mo | Steroids, IVIG | Resistant to multiple treatments | ||
| 35 | M | 11 | 9 | 8 y | Imuran, prednisone | Resistant to multiple treatments; splenectomized | ||
| 36* | F | 13 | 59 | 9 mo | — | — | ||
| Self-limited acute ITP (blood was collected within 6 mo of diagnosis when the patient had active disease; patient resolved within 6 mo) | 5 | 37 | M | 4 | 105 | 1 mo | — | — |
| 38 | F | 5.5 | 128 | 2 mo | — | — | ||
| 39 | F | 13 | 128 | 5 mo | — | — | ||
| 40 | M | 5 | 62 | 2 wk | Steroids | — | ||
| 41 | M | 1 | 128 | 5 mo | Steroids | — | ||
| Glutathione measurement by LC-MS/MS | ||||||||
| Progression to chronic ITP (blood was collected within 6 mo of diagnosis, and the patient did not resolve by 6 mo) | 4 | 42 | F | 3 | 95 | 2 mo | — | — |
| 43 | F | 4 | 4 | 2 mo | — | — | ||
| 44 | M | 17 | 13 | 1 d | IVIG | — | ||
| 45 | M | 13 | 47 | 6 mo | Steroids | — | ||
| Outcome status pending (blood was collected within 6 mo of diagnosis, and whether the patient will resolve by 6 mo remains pending) | 2 | 46 | F | 4.5 | 4 | 2 d | — | — |
| 47 | M | 9 | 7 | 2 wk | — | — | ||
| Chronic ITP (blood was collected after 6 mo of diagnosis when the patient had active disease) | 16 | 48 | M | 5 | 4 | 2 y | — | — |
| 49 | F | 9 | 4 | 2 y | — | — | ||
| 50 | M | 3 | 69 | 2 y | — | — | ||
| 51 | M | 12 | 80 | 2 y | — | — | ||
| 52 | F | 17.5 | 94 | 6 mo | — | — | ||
| 53 | M | 16 | 81 | 14 y | — | — | ||
| 54 | M | 7 | 41 | 2 y | — | — | ||
| 55 | F | 16 | 88 | 1 y | — | — | ||
| 56 | M | 14 | 27 | 11 y | — | — | ||
| 57 | F | 8 | 4 | 1 y | — | — | ||
| 58 | F | 11 | 18 | 5 y | — | — | ||
| 59 | M | 4 | 36 | 1 y | — | — | ||
| 60 | F | 5.5 | 121 | 1 y | — | — | ||
| 61 | F | 4 | 132 | 3 y | — | — | ||
| 62 | M | 16 | 34 | 2 y | Steroids | — | ||
| 63 | F | 6 | 131 | 2 y | Steroids | — |
| Experiment/category of ITP samples based on disease progression . | No. of samples . | Sample ID . | Sex . | Age, y . | Platelet count at time of blood draw, × 109/L . | Time from diagnosis . | Recent treatments (within 1 mo of sample collection) . | Additional information . |
|---|---|---|---|---|---|---|---|---|
| Microarray and/or real-time PCR | ||||||||
| Self-limited acute ITP (blood was collected within 6 mo of diagnosis when the patients had active disease; patients resolved within 6 mo) | 8 | 1* | M | 4 | 2 | 1 d | IVIG | — |
| 2* | M | 4 | 98 | 3 d | IVIG | — | ||
| 3* | F | 14 | 39 | 1 wk | — | — | ||
| 4* | M | 5 | 44 | 1 mo | — | — | ||
| 5* | M | 1 | 35 | 1 mo | — | — | ||
| 6* | M | 13 | 51 | 1 wk | — | — | ||
| 7* | M | 5 | 126 | 2 mo | — | — | ||
| 8* | M | 3 | 146 | 1 wk | — | — | ||
| Progression to chronic ITP (blood was collected within 6 mo of diagnosis, and the patient did not resolve by 6 mo) | 7 | 9* | M | 1 | 24 | 2 wk | IVIG | — |
| 10* | F | 1 | 6 | 2 mo | Steroids | — | ||
| 11* | M | 1 | 39 | 2 mo | — | — | ||
| 12* | F | 9 | 3 | 4 mo | — | — | ||
| 13 | M | 1 | 30 | 5 mo | — | — | ||
| 14 | F | 18 | 49 | 5 mo | — | — | ||
| 15 | F | 6 | 1 | 1 mo | — | — | ||
| Resolved acute ITP (blood was collected after the patient resolved from self-limited acute ITP) | 6 | 16 | M | 4 | 325 | 3 mo | — | — |
| 17 | M | 5 | 249 | 6 mo | — | — | ||
| 18 | M | 1 | 342 | 8 mo | — | — | ||
| 19 | M | 1 | 216 | 3 wk | IVIG | — | ||
| 20 | M | 4 | 276 | 7 mo | — | — | ||
| 21 | M | 4 | 270 | 1 mo | — | — | ||
| Chronic ITP (blood was collected after 6 mo of diagnosis when the patient had active disease) | 15 | 22* | F | 7 | 8 | 2 y | — | Resistant to multiple treatments |
| 23* | F | 13 | 137 | 7 y | — | |||
| 24* | F | 18 | 3 | 6 y | Imuran | Resistant to multiple treatments; splenectomized | ||
| 25* | F | 8 | 111 | 1 y | — | |||
| 26* | M | 5 | 19 | 8 mo | Steroids | — | ||
| 27* | F | 9 | 80 | 3 y | — | — | ||
| 28* | M | 12 | 21 | 1 y | — | — | ||
| 29* | M | 13 | 80 | 3 y | — | — | ||
| 30* | M | 10 | 18 | 7 y | Imuran | Resistant to multiple treatments; splenectomized | ||
| 31* | M | 5 | 53 | 1 y | Bactrim for impetigo | |||
| 32* | M | 14 | 61 | 11 y | — | Resistant to multiple treatments | ||
| 33* | F | 5 | 85 | 3 y | — | — | ||
| 34* | M | 18 | 18 | 9 mo | Steroids, IVIG | Resistant to multiple treatments | ||
| 35 | M | 11 | 9 | 8 y | Imuran, prednisone | Resistant to multiple treatments; splenectomized | ||
| 36* | F | 13 | 59 | 9 mo | — | — | ||
| Self-limited acute ITP (blood was collected within 6 mo of diagnosis when the patient had active disease; patient resolved within 6 mo) | 5 | 37 | M | 4 | 105 | 1 mo | — | — |
| 38 | F | 5.5 | 128 | 2 mo | — | — | ||
| 39 | F | 13 | 128 | 5 mo | — | — | ||
| 40 | M | 5 | 62 | 2 wk | Steroids | — | ||
| 41 | M | 1 | 128 | 5 mo | Steroids | — | ||
| Glutathione measurement by LC-MS/MS | ||||||||
| Progression to chronic ITP (blood was collected within 6 mo of diagnosis, and the patient did not resolve by 6 mo) | 4 | 42 | F | 3 | 95 | 2 mo | — | — |
| 43 | F | 4 | 4 | 2 mo | — | — | ||
| 44 | M | 17 | 13 | 1 d | IVIG | — | ||
| 45 | M | 13 | 47 | 6 mo | Steroids | — | ||
| Outcome status pending (blood was collected within 6 mo of diagnosis, and whether the patient will resolve by 6 mo remains pending) | 2 | 46 | F | 4.5 | 4 | 2 d | — | — |
| 47 | M | 9 | 7 | 2 wk | — | — | ||
| Chronic ITP (blood was collected after 6 mo of diagnosis when the patient had active disease) | 16 | 48 | M | 5 | 4 | 2 y | — | — |
| 49 | F | 9 | 4 | 2 y | — | — | ||
| 50 | M | 3 | 69 | 2 y | — | — | ||
| 51 | M | 12 | 80 | 2 y | — | — | ||
| 52 | F | 17.5 | 94 | 6 mo | — | — | ||
| 53 | M | 16 | 81 | 14 y | — | — | ||
| 54 | M | 7 | 41 | 2 y | — | — | ||
| 55 | F | 16 | 88 | 1 y | — | — | ||
| 56 | M | 14 | 27 | 11 y | — | — | ||
| 57 | F | 8 | 4 | 1 y | — | — | ||
| 58 | F | 11 | 18 | 5 y | — | — | ||
| 59 | M | 4 | 36 | 1 y | — | — | ||
| 60 | F | 5.5 | 121 | 1 y | — | — | ||
| 61 | F | 4 | 132 | 3 y | — | — | ||
| 62 | M | 16 | 34 | 2 y | Steroids | — | ||
| 63 | F | 6 | 131 | 2 y | Steroids | — |
IVIG indicates intravenous immunoglobulin; —, not applicable; and LC-MS/MS, liquid chromatography–tandem mass spectrometry.
The samples were used in microarray analysis. All samples numbered between 1 and 36 were used in real-time PCR analysis except for samples 1, 2, 6, 23, and 35.